BioCentury | Jul 3, 2020
Translation in Brief

Tesla developing RNA therapeutic ‘microfactories’ for CureVac, plus CRISPR-directed RNA epigenetic modifications and Nucleix

...Tesla ‘microfactories’ for CureVac Elon Musk tweeted on Wednesday that Tesla Grohmann Automation GmbH unit of...
BioCentury | Apr 24, 2020
Politics, Policy & Law

FDA warns about dangers of hydroxychloroquine, chloroquine for COVID-19

...dangers are increased by the addition of the antibiotic azithromycin, a regimen Trump and Elon Musk...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...TNFSF13B) - BLyS C5 - Complement 5 FCRN (FCGRT) - Neonatal Fc receptor MUSK - Muscle associated receptor tyrosine kinase Stephen...
BioCentury | Jan 13, 2020
Politics & Policy

Supreme Court declines to clean up its IP mess

...MUSK) in causing the neurological disorder and developed a method for diagnosing it by detecting MUSK...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...leads to B cell killing. Cabaletta will present preclinical data on its second program for MUSK...
...diseases,” said Gladstone. Targets DSG3 - Desmoglein 3 FAP - Fibroblast activation protein MUSK - Muscle associated receptor tyrosine kinase Lauren...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Firdapse amifampridine phosphate Treat myasthenia gravis in patients with anti-muscle associated receptor tyrosine kinase (MUSK) antibodies (MUSK-MG...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Pharmaceutical Inc. (NASDAQ:BMRN) / Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Firdapse amifampridine Myasthenia gravis in patients with anti-muscle associated receptor tyrosine kinase (MUSK)...
BioCentury | Dec 1, 2017
Financial News

Catalyst raises $50M in follow-on

...Phase III trial of the candidate to treat myasthenia gravis in patients with anti-muscle associated receptor tyrosine kinase (MUSK) antibodies (MUSK-MG...
...1Q18. In March, Firdapse met the co-primary endpoints in a Phase II/III trial to treat MUSK-MG...
BioCentury | Nov 28, 2017
Financial News

Catalyst raises $50M in follow-on

...Phase III trial of the candidate to treat myasthenia gravis in patients with anti-muscle associated receptor tyrosine kinase (MUSK) antibodies (MUSK-MG...
...1Q18. In March, Firdapse met the co-primary endpoints in a Phase II/III trial to treat MUSK-MG...
BioCentury | Mar 17, 2017
Clinical News

Firdapse: Ph II/III data

...Top-line data from a double-blind, crossover, Italian Phase II/III trial in 7 MUSK-MG patients showed that...
...May. The company hopes to meet with FDA next quarter to discuss a registration trial. MUSK-MG...
...channel Description: Potassium channel blocker Indication: Treat myasthenia gravis in patients with anti- muscle associated receptor tyrosine kinase (MUSK) antibodies (MUSK-MG...
Items per page:
1 - 10 of 16